Kamada says CYTOGAM study links CMV immunoglobulin prophylaxis to improved outcomes in high-risk lung transplant patients
KMDA•Management expects support for utilization
Management expects the post-marketing program to support increased CYTOGAM utilization; full study results are expected to be published later this year.
Preclinical model supports a possible mechanism
Non-clinical in-vivo model found CMVIG blunted acute lung injury and improved mortality, supporting a potential immune-modulating mechanism.
Study links CYTOGAM prophylaxis to better outcomes
Kamada highlighted investigator-initiated data suggesting CYTOGAM prophylaxis in high-risk lung transplants was linked to better outcomes versus no CMVIG.
Retrospective analysis showed worse clinical outcomes without CMVIG; paired blood-cell work indicated lower innate immune activation with CMVIG prophylaxis.
